ACUMEN PHARMACEUTICALS INC (ABOS) Stock Earnings Estimates
NASDAQ:ABOS • US00509G2093
2.51 USD
+0.12 (+5.02%)
Last: Feb 13, 2026, 08:00 PM
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.7M | 1.44M -15.29% | -100.00% | 26.928M | 71.706M 166.29% | 122.3M 70.56% | ||||||||||
| EBITDA YoY % growth | N/A | N/A | -16.395M | -41.206M -130.90% | -58.074M -34.79% | -108.059M -86.97% | -134.057M -17.66% | 28.197B 21,133.66% | 45.049B 59.77% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.81M | -7.91M -1.28% | -37.949M -147.53% | -42.101M -131.05% | -59.947M -34.84% | -105.903M -86.89% | -130.45M -14.43% | -113.772M 12.78% | -126.251M -10.97% | -69.392M 45.04% | -122.38M -76.36% | -113.096M 7.59% | -100.638M 11.02% | -31.968M 68.23% | 99.723M 411.94% | |
| Operating Margin | -459.41% | -549.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -373.73% | -44.58% | 81.54% | |
| EPS YoY % growth | N/A | N/A | -3.78 | -1.00 71.98% | -1.09 -1.89% | -1.61 -58.33% | -2.09 -22.12% | -1.68 19.55% | -1.49 11.60% | -2.20 -48.35% | -2.07 6.02% | -0.36 82.76% | 0.64 280.00% | 2.13 231.75% | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 25.45% | -0.39 19.25% | -0.37 45.50% | -0.37 16.55% | -0.31 32.70% | -0.17 55.26% | -0.17 53.21% | -0.18 50.00% | -0.18 40.98% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | -31.369M 20.65% | -29.549M 2.65% | -30.233M 27.53% | -29.274M -10.61% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -29.574M 25.31% | -24.805M 18.32% | -23.29M 44.22% | -23.146M 12.70% | -17.717M 40.09% | -18.249M 26.43% | -18.797M 19.29% | -19.361M 16.35% | -19.941M -12.55% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.44 12.00% | -0.62 | 0.18 | 28.53% |
| Q2 2025 Q2Q % growth | -0.68 -100.00% | -0.55 | -0.13 | -23.92% |
| Q1 2025 Q2Q % growth | -0.48 -92.00% | -0.68 | 0.20 | 29.06% |
| Q4 2024 Q2Q % growth | -0.62 -121.43% | -0.49 | -0.13 | -26.63% |
| Q3 2024 Q2Q % growth | -0.50 -108.33% | -0.37 | -0.13 | -34.30% |
| Q2 2024 Q2Q % growth | -0.34 -21.43% | -0.29 | -0.05 | -19.05% |
| Q1 2024 Q2Q % growth | -0.25 10.71% | -0.27 | 0.02 | 5.73% |
| Q4 2023 Q2Q % growth | -0.28 12.50% | -0.27 | -0.01 | -5.58% |
| Q3 2023 Q2Q % growth | -0.24 7.69% | -0.27 | 0.03 | 11.54% |
| Q2 2023 Q2Q % growth | -0.28 -12.00% | -0.35 | 0.07 | 20.66% |
| Q1 2023 Q2Q % growth | -0.28 -21.74% | -0.35 | 0.07 | 20.66% |
| Q4 2022 Q2Q % growth | -0.32 23.08% | -0.26 | -0.06 | -22.84% |
| Q3 2022 Q2Q % growth | -0.26 -160.00% | -0.23 | -0.03 | -10.92% |
| Q2 2022 Q2Q % growth | -0.25 96.84% | -0.25 | 0.00 | -0.04% |
| Q1 2022 Q2Q % growth | -0.23 | -0.17 | -0.06 | -35.84% |
| Q4 2021 Q2Q % growth | -0.42 | -0.14 | -0.27 | -187.21% |
| Q3 2021 Q2Q % growth | -0.10 | -0.17 | 0.07 | 42.44% |
| Q2 2021 Q2Q % growth | -7.91 | -4.65 | -3.26 | -70.21% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -100.00% | % | ||
| Q3 2021 Q2Q % growth | -100.00% | % | ||
| Q2 2021 Q2Q % growth | -100.00% | % | ||
| Q1 2021 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 14.98% | -0.08% | 10.85% |
| Revenue | N/A | N/A | N/A | N/A |